日本臨牀 74/増刊7 脳腫瘍学

出版社: 日本臨牀社
発行日: 2016-09-20
分野: 臨床医学:一般  >  雑誌
ISSN: 00471852
雑誌名:
特集: 脳腫瘍学 基礎研究と臨床研究の進歩
電子書籍版: 2016-09-20 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

20,900 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

20,900 円(税込)

目次

  • 日本臨牀 74/増刊7 脳腫瘍学

    ―目次―

    特集 脳腫瘍学 基礎研究と臨床研究の進歩

    I.総 論
    1.脳腫瘍病理診断の変遷と展望
    2.脳腫瘍画像診断の変遷と展望
    3.脳腫瘍外科治療の歴史と展望
    4.脳腫瘍化学療法の変遷と展望
    5.脳腫瘍放射線治療の変遷と展望
    6.脳腫瘍治療の新たな潮流−TTFは標準治療となるか−

    II.脳腫瘍の疫学と危険因子
    1.日本の脳腫瘍の疫学的動向
       −脳腫瘍全国集計調査報告に基づく
        国内脳腫瘍登録データの変遷−
    2.脳腫瘍の疫学―国際比較―
    3.脳腫瘍の危険因子
    4.脳腫瘍の部位別発症頻度と問題点

    III.脳腫瘍の分子生物学と発生機序
    1.分子生物学
    2.発生機序

    IV.脳腫瘍の病理学
    1.脳腫瘍の病理学:概論
    2.胎児性腫瘍
    3.限局性星細胞腫
    4.乏突起膠腫
    5.成人びまん浸潤性星細胞腫 WHO grade II/III
    6.膠芽腫
    7.上衣腫
    8.神経細胞膠細胞腫瘍
    9.髄膜腫
    10.神経鞘腫
    11.トルコ鞍近傍腫瘍
    12.松果体部近傍腫瘍
    13.胚細胞性腫瘍
    14.頭蓋内原発悪性リンパ腫
    15.骨腫瘍

    V.脳腫瘍の浸潤・転移
    1.脳腫瘍浸潤の基礎と臨床
    2.浸潤・転移関連遺伝子MCAM/CD146
    3.転移性脳腫瘍における浸潤形態と再発

    VI.脳腫瘍の予後因子
    1.脳腫瘍の予後因子:概論
    2.頭蓋底髄膜腫の予後予測因子
    3.髄芽腫の予後因子Gli3
    4.膠芽腫長期生存例の臨床病理学的特徴−多施設共同研究−
    5.頭蓋内血管周皮腫の他臓器遠隔転移と予後因子

    VII.脳腫瘍治療ガイドライン・脳腫瘍取扱い規約
    1.膠芽腫
    2.中枢神経系原発悪性リンパ腫
    3.転移性脳腫瘍
    4.小児脳腫瘍:ガイドライン作成にあたって

    VIII.脳腫瘍の検査・診断
    1.脳腫瘍の検査・診断:概論
    2.脳腫瘍
    3.転移・再発巣
    4.脳腫瘍の病理検査・診断
    5.脳腫瘍の分子生物学的検査と予後

    IX.脳腫瘍の治療
    1.脳腫瘍の治療:概論
    2.脳腫瘍の外科的治療
    3.脳腫瘍の放射線療法
    4.脳腫瘍の化学療法
    5.脳腫瘍の分子標的治療
    6.免疫療法

    X.小児脳腫瘍
    1.小児脳腫瘍:概論
    2.髄芽腫
    3.非定型奇形腫様ラブドイド腫瘍
    4.小児上衣腫の治療
    5.脳幹部膠腫
    6.視神経膠腫
    7.頭蓋咽頭腫
    8.胚 腫

    XI.転移性脳腫瘍
    1.検査・診断
    2.治 療

    XII.特 論
    1.DDS (Drug Delivery System)
    2.ワクチン療法(WT1)
    3.ワクチン療法
    4.脳腫瘍の遺伝子治療
    5.ウイルス療法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 総論

P.15 掲載の参考文献
1) 高倉公朋 : 脳腫瘍病理の歴史. 脳腫瘍臨床病理カラーアトラス (日本脳腫瘍病理学会編), p3-6, 医学書院, 2009.
2) 中里陽一 : 脳腫瘍WHO分類の歴史. Neuro-Oncologyの進歩 21 : 1-9, 2014.
6) 中里陽一 : 改訂された脳腫瘍WHO分類. Brain and nerve 60 : 59-77, 2008.
7) 中里陽一 : 脳腫瘍WHO分類の作製に貢献した日本人. Neuro-Oncologyの進歩 19 : 76-79, 2010.
8) 中里陽一 : 脳腫瘍のWHO分類, 現状と展望. 日本臨牀 68 : 120-126, 2010.
9) Louis DN, et al : WHO Classfication of Tumours of the Central Nervous System, International agency for research on cancer, Lyon, 2016.
13) 所安夫 : 脳腫瘍, 医学書院, 1959.
P.23 掲載の参考文献
10) Wester HJ, et al : Synthesis and radiopharmacology of O- (2- [18F] fluoroethyl) -L-tyrosine for tumor imaging. J Nucl Med 40 : 205-212, 1999.
12) Kawai N, et al : Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging 41 : 1870-1878, 2014.
P.30 掲載の参考文献
9) Schloffer H : Erfolgreiche Operation eines Hypophysentumors auf nasalen Wege. Wien Klin Wschr 20 : 621-624, 1907.
P.35 掲載の参考文献
3) Hirose Y, et al : p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61 : 47-63, 2001.
4) Cairncross JG, et al : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 : 1473-1479, 1998.
14) Sonoda Y, et al : Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 61 : 6674-6678, 2001.
15) Nogueira L, et al : The NFκB pathway : a therapeutic target in glioblastoma. Oncotarget 2 : 646-653, 2011.
P.41 掲載の参考文献
2) Walker MD, et al : An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5 : 1725-1731, 1979.
6) Sharma RR, et al : Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurol India 51 : 512-517, 2003.
7) Souhami L, et al : Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60 : 853-860, 2004.
P.47 掲載の参考文献

II 脳腫瘍の疫学と危険因子

P.58 掲載の参考文献
1) 脳腫瘍全国統計委員会 : 脳腫瘍全国集計調査報告, Vol. 7 (1969-1983), p 1-165, 1990.
2) Committee of Brain Tumor Registry of Japan : Report of Brain Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 49 (Suppl) : PS1-96, 2009.
4) Lacroix M, et al : A multivariate analysis of 416 patients with glioblastoma multiforme : prognosis, extent of resection, and survival. J Neurosurg 95 : 190-198, 2001.
P.69 掲載の参考文献
P.71 掲載の参考文献
P.76 掲載の参考文献
8) Zhukova N, et al : Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol 31 : 2927-2935, 2013.
15) Rajaraman P, et al : Genome-wide association study of glioma and meta-analysis. Hum Genet 131 : 1877-1888, 2012.
P.82 掲載の参考文献
P.87 掲載の参考文献
5) WHO Electromagnetic fields (EMF). [http://www.who.int/peh-emf/research/agenda/en/] (2016. 2. 26 accessed)
6) 国立研究開発法人国立がん研究センターがん情報センター : がんの統計 '14. [http://ganjoho.jp/reg_stat/statistics/brochure/backnumber/2014_jp.html] (2016. 2. 26 accessed)
7) Ding LX, Wang YX : Increasing incidence of brain and nervous tumours in urban Shanghai, China, 1983-2007. Asian Pac J Cancer Prev 12 : 3319-3322, 2011.
8) 小島原典子, 山口直人 : 高周波電磁界の疫学研究の動向. 保健医療科学 64 : 540-545, 2015.
13) Sadetzki S, et al : The MOBI-Kids Study Protocol : ChaUenges in Assessing Childhood and Adolescent Exposure to Electromagnetic Fields from Wireless Telecommunication Technologies and Possible Association with Brain Tumor Risk. Front Public Health 2 : 124, 2014.
15) Sound Exposure & Risk Assessment of Wireless Network Devices (SEAWIND). FP7-ENV-2009-1 Final Summary Report. [http://seawind-fp7.eu/uploads/SEAWIND_FINAL.pdf] (2016. 2. 26 accessed)
16) Visual Display Units : Radiation Protection Guidance, Occupational Safety and Health Series No. 70, International Labour Office, Genova, 1994.
P.91 掲載の参考文献
5) Preston-Martin S, et al : Risk factors for gliomas and meningiomas in males in Los Angeles County. Cancer Res 49 : 6137-6143, 1989.
15) Gomes J, et al : Occupational and environmental risk factors of adult primary brain cancers : A systematic review. Int J Occup Envoron Med 2 : 82-111, 2011.
P.94 掲載の参考文献
1) IARC : Tabacco smoke and involuntary smoking. IARC Monographs Evaluating the Carcinogenic Risks in Humans, Vol 83, World Health Organization, Geneva, 2004.
2) Preston-Martin S, et al : N-nitroso compounds and childhood brain tumors : a case-control study. Cancer Res 42 : 5240-5245, 1982.
4) 中洲庸子 : 脳腫瘍と喫煙のエビデンス. 医学のあゆみ 226 : 500-502, 2008.
5) Zheng T, et al : Risk of brain glioma not associated with cigarette smoking or use of other tabacco products in Iowa. Cancer Epidemiol Biomarkers Prev 10 : 413-414, 2001.
P.99 掲載の参考文献

III 脳腫瘍の分子生物学と発生機序

P.109 掲載の参考文献
6) Pajtler KW, et al : Molecular Classhication of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27 : 728-743, 2015.
14) Shih DJ, et al : Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32 : 886-896, 2014.
17) Mack SC, et al : Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 : 445-450, 2014.
18) Parker M, et al : Cllorf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506 : 451-455, 2014.
P.115 掲載の参考文献
2) Verhaak RGW, et al : Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA IDH1, EGFR and NF1. Cancer Cell 17 : 98-110, 2010.
5) WHO Classification of Tumours of the Central Nervous System, 4th ed (ed by Louis DN, et al), WHO, 2007.
10) The Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
P.121 掲載の参考文献
13) Brennan CW, et al : The somatic genomic landscape of glioblastoma. Cell 155 : 462-477, 2013.
P.125 掲載の参考文献
1) Reifenberger J, et al : Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1P. Am J pathol 145 : 1175-1190, 1994.
3) Cairncross JG, et al : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 : 1473-1479, 1998.
P.130 掲載の参考文献
7) Lin H, et al : Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas : relationship to prognostic significance. Clin Cancer Res 4 (10) : 2447-2454, 1998.
9) Rasheed BK, et al : Chromosome 10 deletion mapping in human gliomas : a common deletion region in 10q25. Oncogene 10 (11) : 2243-2246, 1995.
13) Ramirez C, et al : Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors-towards individualized tumor treatment? Neuro Oncol 12 (5) : 490-499, 2010.
16) Li DM, Sun H : TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57 (11) : 2124-2129, 1997.
18) Li J, et al : The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58 (24) : 5667-5672, 1998.
21) Tamura M, et al : Tumor suppressor PTEN inhibition of cell invasion, migration, and growth : differential involvement of focal adhesion kinase and p130Cas. Cancer Res 59 (2) : 442-449, 1999.
24) Gottschalk AR, et al : p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res 61 (5) : 2105-2111, 2001.
36) Mellinghoff IK, et al : Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (19) : 2012-2024, 2005.
P.135 掲載の参考文献
2) Hiraga S, et al : Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 58 : 2117-2125, 1998.
8) Kllela PJ, et al : TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110 : 6021-6026, 2013.
15) Remke M, et al : TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 126 : 917-929, 2013.
P.142 掲載の参考文献
9) Schwartzentruber J, et al : Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 : 226-231, 2012.
10) Sturm D, et al : Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22 : 425-437, 2012.
P.146 掲載の参考文献
P.153 掲載の参考文献
3) Brennan CW, et al : The somatic genomic landscape of glioblastoma. Cell 155 : 462-477, 2013.
P.157 掲載の参考文献
2) Hermanson M, et al : Platelet-derived growth factor and its receptors in human glioma tissue : expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52 (11) : 3213-3219, 1992.
8) Wolfe LG, et al : Induction of tumors in mamioset monkeys by simian sarcoma virus, type 1 (Lagothris) : a preliminary report. J Natl Cancer Inst 47 (5) : 1115-1120, 1971.
13) Kilic T, et al : Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60 (18) : 5143-5150, 2000.
P.164 掲載の参考文献
5) Esteller M, et al : Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59 : 793-797, 1999.
9) Palmisano WA, et al : Predicting lung cancer by detecting aberrant promoter methylation in sputum Cancer Res 60 : 5954-5958, 2000.
26) 佐々木光 : グリオーマに対する化学療法-最新のエビデンスを中心に-. 脳神経外科ジャーナル 23 : 547-558, 2014.
30) 佐々木光, 吉田一成 : 神経膠腫における分子診断と個別化治療. 脳神経外科 44 : 185-201, 2016.
P.170 掲載の参考文献

IV 脳腫瘍の病理学

P.178 掲載の参考文献
P.186 掲載の参考文献
P.191 掲載の参考文献
1) WHO Classhication of Tumours of the Central Nervous System (ed by Louis DN, et al), IARC Press, Lyon, 2016.
2) 脳腫瘍取扱い規約 (日本脳神経外科学会, 日本病理学会編), 金原出版, 2010.
5) WHO Classhication of Tumours of the Central Nervous System (ed by Louis DN, et al), IARC Press, Lyon, 2007.
P.195 掲載の参考文献
1) Reifenberger G, et al : Oligodendroglioma. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 54-59, IARC, Lyon, 2007.
2) Reifenberger G, et al : Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. In : WHO Classification of Tumours of the Central Nervous System (Revised 4th edition) (ed by Louis DN, et al), p 60-69, IARC, Lyon, 2016.
3) Reifenberger G, et al : Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted. In : WHO Classification of Tumours of the Central Nervous System (Revised 4th edition) (ed by Louis DN, et al), p 70-74, IARC, Lyon, 2016.
4) Reifenberger G, et al : Oligoastrocytoma, NOS. In : WHO Classhication of Tumours of the Central Nervous System (Revised 4th edition) (ed by Louis DN, et al), p 75-77, IARC, Lyon, 2016.
P.202 掲載の参考文献
1) Louis NL, et al : WHO classification of Tumours of the Central Nervous System, revised 4th ed (ed by Louis NL, et al), LARC press, Lyon, 2016.
3) 増井憲太, 小森隆司 : 神経病理診断の標準化 II [外科病理] 脳腫瘍病理診断-up-to-date-. 病理と臨床 33 : 380-387, 2015.
12) Louis NL, et al : WHO classification of Tumours of the Central Nervous System (ed by Louis NL, et al), IARC press, Lyon, 2007.
P.208 掲載の参考文献
1) Kleihues P, et al : Glioblastoma. In : WHO Classification of Tumours of the Central Nervous System, 4th ed (ed by Louis DN, et al), p 33-49, International Agency for Research on Cancer, Lyon, 2007.
3) Louis DN, et al (ed) : WHO Classification of Tumours of the Central Nervous System, revised 4th ed, International Agency for Research on Cancer, Lyon, 2016.
4) Daumas-Duport C, et al : Grading of astrocytomas. A simple and reproducible method. Cancer 62 : 2152-2165, 1988.
P.213 掲載の参考文献
1) WHO Classification of Tumours of the Central Nervous System, revised 4th edition (ed by Louis DN, et al), IARC, Lyon, 2016.
2) Parker M, et al : C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma. Nature 506 : 451-455, 2014.
3) WHO Classification of Tumours of the Central Nervous System, 4th edition (ed by Louis DN, et al), IARC, Lyon, 2007.
P.221 掲載の参考文献
1) WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 132-167, International Agency for Research on Cancer, Lyon, 2016.
2) 臨床・病理 脳腫瘍取扱い規約 臨床と病理カラーアトラス (日本脳神経外科学会・日本病理学会編), p113-119, 金原出版, 2010.
P.232 掲載の参考文献
1) WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), IARC, Lyon, 2016.
3) 臨床・病理 脳腫瘍取扱い規約 第3版 (社団法人日本脳神経外科学会, 社団法人日本病理学会編), 金原出版, 2010.
6) Peknezci M, et al : Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Mod Pathol 28 : 187-200, 2015.
P.237 掲載の参考文献
1) Buslei R, et al : Craniopharyngioma. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 324-328, IARC, Lyon, 2016.
2) Fuller GN, et al : Granular cell tumour of the sellar region. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 329-331, IARC, Lyon, 2016.
3) Brat DJ, et al : Pituicytoma. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 332-333, IARC, Lyon, 2016.
4) Lopes MBS, et al : Spindle cell oncocytoma. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 334-336, IARC, Lyon, 2016.
P.241 掲載の参考文献
1) Nakazato Y, et al : Tumours of the pineal regions. In : WHO Classification of Tumours of the Central Nervous System Update 4th ed (ed by Louis DN, et al), IARC Press, Lyon, 2016.
P.247 掲載の参考文献
1) Rosenblum MK, et al : Germ cell tumours. In : WHO Classhication of Tumours of the Central Nervous System, Revised 4th ed (ed by Louis DN, et al), p 285-291, International Agency for Research on Cancer (IARC), Lyon, 2016.
3) Burger PC, et al : Chapter 4. The Brain : Tumors. In : Surgical Pathology of the Nervous System and Its Coverings, 4th ed (ed by Burger PC, et al), p 160-378, Churchill Livingstone, Philadelphia, 2002.
4) 臨床・病理 脳腫瘍取扱い規約 (第3版) 臨床と病理カラーアトラス (日本脳神経外科学会・日本病理学会編), 金原出版, 2010.
5) 佐々木惇 : 松果体部腫瘍の病理診断 (Pathological diagnosis of the pineal region tumors). Neuro-Oncologyの進歩 (Progress in Neuro-Oncology) 18 : 1-8, 2013.
P.252 掲載の参考文献
2) Louis DN, et al : WHO Classification of Tumours of the Central Nervous System, revised 4th ed, p272-277, International Agency for Research on Cancer, Lyon, 2016.
8) 西原広史, 立石宇貴秀 : リンパ腫様肉芽腫症. 別冊日本臨牀 免疫症候群 (第2版) (1), p725-728, 日本臨牀社, 2015.
P.258 掲載の参考文献
1) Grimer RJ, et al : Tumours of bone : Introduction. In : WHO Classhication of Tumours of Soft Tissue and Bone (ed by Fletcher CD, et al), p 244-247, International Agency for Research on Cancer, Lyon, 2013.
2) 河本桂司ほか : 頭蓋骨腫瘍の臨床と病理 (1) 頭蓋骨腫瘍分類・軟骨腫・良性軟骨芽細胞腫・軟骨肉腫. 脳神経外科 32 : 427-435, 2004.
3) 石田剛 : 骨腫瘍の分類と組織診断. 骨腫瘍の病理 (石田剛編), p10-22, 文光堂, 2012.
4) 石田剛 : 骨腫瘍の分類と組織診断. 骨腫瘍の病理 (石田剛編), p36-40, 文光堂, 2012.

V 脳腫瘍の浸潤・転移

P.266 掲載の参考文献
12) Wild-Bode C, et al : Sublethal irradiation promotes migration and invasiveness of glioma cells : implications for radiotherapy of human glioblastoma. Cancer Res 61 : 2744-2750, 2001.
P.273 掲載の参考文献
3) Xie S, et al : Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 57 : 2295-2303, 1997.
5) Heimberger AB, et al : Loss of the AP-2 alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res 11 : 267-272, 2005.
6) Jean D, et al : Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 273 : 16501-16508, 1998.
10) Ishikawa T, et al : Laminins 411 and 421 differentially promote tumor cell migration Via α6β1 integrin and MCAM (CD146). Matrix Biol 38 : 69-83, 2014.
P.277 掲載の参考文献
4) Fidler U : Critical factors in the biology of human cancer metastasis : twenty-eighth G. H. A. Clowes memorial award lecture. Cancer Res 50 (19) : 6130-6138, 1990.
6) Neves S, et al : Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain. Clin Neuropathol 20 (1) : 38-42, 2001.
14) Yamamoto M, et al : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 15 (4) : 387-395, 2014.
17) Kocher M, et al : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 29 (2) : 134-141, 2011.

VI 脳腫瘍の予後因子

P.284 掲載の参考文献
14) Shih DJ, et al : Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32 : 886-896, 2014.
15) Pajtler KW, et al : Molecular Classhication of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27 : 728-743, 2015.
P.291 掲載の参考文献
13) Ciocan LM, et al : Prognostic factors in anterior skull base meningiomas. Rom J Morphol Embryol 55 (3 Suppl) : 1063-1069, 2014.
P.296 掲載の参考文献
2) Ellison DW, et al : β-Catenin status predicts a favorable outcome in childhood medulloblastoma : The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23 : 7951-7957, 2005.
5) Northcott PA, et al : Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nautre 488 : 49-56, 2012.
9) 吉村淳一ほか : 髄芽腫に対する集学的治療と治療成績. 小児の脳神経 33 : 525-530, 2008.
11) 細貝亮介ほか : 全脳脊髄照射を要する小児脳腫瘍における術後2週間以内のG-CSF単独自家末梢血幹細胞採取. 日本小児血液・がん学会雑誌 52 : 133-138, 2015.
P.306 掲載の参考文献
P.311 掲載の参考文献

VII 脳腫瘍治療ガイドライン・脳腫瘍取扱い規約

P.318 掲載の参考文献
P.332 掲載の参考文献
2) Deckert M, et al : World Health Organization Histological Classification of Tumours of the Central Nervous System (ed by Louis DN, et al) p188-192, IARC, Lyon, 2007.
33) Khan RB, et al : Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58 : 175-178, 2002.
38) Ferreri AJ, et al : Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma : results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 3 : e217-227, 2016.
57) Mishima K : Treatment of recurrent primary central nerve system lymphoma. Gan To Kagaku Ryoho 39 : 898-905, 2012.
P.340 掲載の参考文献
2) 転移性脳腫瘍. 脳神経外科学 II (改訂11版) (川原信隆ほか編, 太田富雄総編集), p 1592-1607, 金芳堂, 2012.
6) O'Neill BP, et al : A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55 : 1169-1176, 2003.
8) 大堀久詔ほか : 転移性脳腫瘍に対する化学療法の役割. 脳神経外科ジャーナル 16 : 840-848, 2007.
P.345 掲載の参考文献

VIII 脳腫瘍の検査・診断

P.354 掲載の参考文献
2) 大石誠ほか : 脳神経外科領域における新規画像診断法. 解剖・機能画像の進歩. 脳神経外科 35 : 291-300, 2007.
3) 広瀬雄一 : 脳腫瘍の病理分類, 分子生物学的解析総論. 脳神経外科 43 : 1119-1128, 2015.
P.359 掲載の参考文献
2) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45 : 575-578, 1988.
11) 水口雅 : 結節性硬化症. 日本臨牀 68 : 208-213, 2010. '
16) 菅野洋 : 家族性脳腫瘍の基礎と臨床. BRAIN and NERVE : 神経研究の進歩 64 : 557-564, 2012.
P.364 掲載の参考文献
2) McLendon RE, et al : Central nervous system primitive neuroectodermal tumours. In : WHO Classification of Tumours of the Central Nervous System, 4th ed (ed by Louis DN, et al), p 141-146. IARC, Lyon, 2007.
3) Judkins AR, et al : Atypical teratoid/rhabdoid tumour. In : WHO Classification of Tumours of the Central Nervous System, 4th ed (ed by Louis DN, et al), p 147-149. IARC, Lyon, 2007.
4) 五味玲 : 小児脳腫瘍の化学療法の最近の進歩. Neuro-Oncologyの進歩 21 : 22-32, 2014.
5) Report of Brain Tumor Registry of Japan (1984-2000). Neurol Med Chir (Tokyo) 49 (Suppl) : PS1-96, 2009.
7) Blaise VJ : Medulloblastoma In : Diagnostic Imaging Pediatric Neuroradiology (ed by Barkovich AJ), pI-4, 10-13, Amirsys, Salt Lake City, 2007.
12) Gary LH : Supratentorial PNET. In : Diagnostic Imaging Pediatric Neuroradiology (ed Barkovich AP, pI-8, 180-183, Amirsys, Salt Lake City, 2007.
14) Blaise VJ : Atypical teratoid-rhabdoid tumor. In : Diagnostic Imaging Pediatric Neuroradiology (ed by Barkovich AJ), pI-8, 82-85, Amirsys, Salt Lake City, 2007.
P.370 掲載の参考文献
P.376 掲載の参考文献
2) Cairncross JG, et al : Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 : 1473-1479, 1998.
P.380 掲載の参考文献
1) Ceccarelli M, et al : Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164 : 550-563, 2016.
8) 西川亮ほか : 初回再発の退形成性星細胞腫患者に対するTemozolomide単剤投与の有効性および安全性の検討 多施設共同第II相試験. 癌と化学療法 33 : 1279-1285, 2006.
P.390 掲載の参考文献
13) 成相直 : グリオーマの診断と治療に有用な放射線診断学の進歩. 脳神経外科ジャーナル 23 : 559-568, 2014.
P.396 掲載の参考文献
9) Ene CI, et al : Safety and Efficacy of Preoperative Embolization of Intracranial Hemangioblastomas. Neurosurgery 2015 Sep 9. [Epub ahead of print]
P.400 掲載の参考文献
1) Louis DN, et al (ed) : WHO Classification of Tumours of the Central Nervous System, 4th ed, International Agency for Research on Cancer, Lyon, 2007.
2) 小森隆司 : 神経膠腫 Mixed neuronal-glial tumors. 日本臨牀 68 (増刊 10) : 137-140, 2010.
3) 廣瀬隆則 : 神経細胞および混合神経細胞・膠細胞系腫瘍の病理. 第30回日本脳腫瘍病理学会, 教育セミナー, テキスト, p67-75, 脳腫瘍病理診断医育成委員会, 2012.
4) 北井隆平 : 神経細胞由来の腫瘍. 脳腫瘍の病理と臨床 (改訂第2版), p123-148, 診断と治療社, 2008.
11) Daumas-Duport C, et al : Dysembryoplastic neuroepithelial tumor : a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 23 : 545-556, 1988.
P.405 掲載の参考文献
1) Report of brain tumor registry of Japan (1984-2000), 12th edition. Neurol Med Chir 49 (Suppl) PS1-96, 2009.
2) Louis N, et al : WHO Classification of Tumours of the Central Nervous System, 4th edition. Internationa Agency for Research on Cancer, Lyon, 2016.
5) Backer-Grondahl T et. al : The histopathological spectrum of human meningiomas. Int J Clin Pathol 5 (3) : 231-242, 2012.
9) Waga S, Handa H : Radiation-induced meningioma : with review of literature. Surg Neurol 5 (4) : 215-219, 1976.
10) 脳ドックのガイドライン 2014改訂・第4版 (日本脳ドック学会脳ドックの新ガイドライン作成委員会編), 響文社, 2014.
11) National Comprehensive Cancer Network ; National Comprehensive Cancer Network, editor. Practice Guidelines in Oncology. 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(TM)).
14) 放射線治療計画ガイドライン 2012年版 (日本放射線腫瘍学会編), 金原出版, 2012.
P.412 掲載の参考文献
2) 河野道宏 : 小脳橋角部腫瘍. 別冊日本臨牀 神経症候群 (第2版) III, p 495-498, 日本臨牀社, 2014.
10) 中島伸幸, 河野道宏 : 頭蓋底手術に必要な画像検査. JOHNS 31 : 831-835, 2015.
P.418 掲載の参考文献
8) Watanabe S, et al : A highly sensitive…and spechic chemiluminescent enzyme immunoassay for placental alkaline phosphatase in the cerebrospinal fluid of patients with intracranial germinomas. Pediatr Neurosurg 48 : 141-145, 2012.
P.424 掲載の参考文献
P.431 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan, The Japanese Pathological Society : General Rules for Clinical and Pathological Studies on Brain Tumors, 2nd ed, p 9-12, Kanehara-Shuppan, Tokyo, 2002.
P.434 掲載の参考文献
1) Deckert M, Paulus W : Malignant lymphomas. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p188-192, IARC, Lyon, 2007.
P.442 掲載の参考文献
1) 石田剛 : 骨の正常構造. 骨腫瘍の病理, p2-10, 文光堂, 2012.
2) 石田剛 : 骨腫瘍の画像所見. 骨腫瘍の病理, p22-27, 文光堂, 2012.
3) 稲木杏吏 : 骨・関節. 核医学テキスト (絹谷清剛編), p146-159, 中外医学社, 2013.
4) 石井清, 梅津篤司 : 頭蓋骨の異常. 脳MRI 3. 血管障害・腫瘍・感染症・他 (高橋昭喜編), p 512-526, 秀潤社, 2010.
5) Lucas DR, Bridge JA : Chondromas : enchondroma, periosteal chondroma, and enchondrosis. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 237-240, IARC Press, Lyon, 2002.
6) 河本圭司, 中嶋安彬 : 軟骨腫 アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p152-153, MCメディカ出版, 2005.
7) Bertoni F, et al : Chondrosarcoma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 247, IARC Press, Lyon, 2002.
8) 河本圭司, 中嶋安彬 : 軟骨肉腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p155-156, MCメディカ出版, 2005.
9) Sugano O, et al : Mesenchymal chondrosarcoma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 255, IARC Press, Lyon, 2002.
10) 河本圭司, 中嶋安彬 : 間葉軟骨肉腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p157, MCメディカ出版, 2005.
11) Schneider-Stock R, et al : Osteoid osteoma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 260, IARC Press, Lyon, 2002.
12) 河本圭司, 中嶋安彬 : 骨腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p 159-160, MCメディカ出版, 2005.
13) Knuutila S, et al : Conventional osteosarcoma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 264-265, IARC Press, Lyon, 2002.
14) 河本圭司, 中嶋安彬 : 骨肉腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p163-165, MCメディカ出版, 2005.
15) Bridge JA, Rubin BP : Myofibroma/myofibromatosis. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 59, IARC Press, Lyon, 2002.
16) 河本圭司, 中嶋安彬 : 筋線維腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p166, MCメディカ出版, 2005.
17) 河本圭司, 中嶋安彬 : Ewing肉腫/PNET群. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p 168, MCメディカ出版, 2005.
18) Lorenzo-Roldan JC, et al : Plasma cell myeloma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 302-303, IARC Press, Lyon, 2002.
19) 河本圭司, 中嶋安彬 : 形質細胞腫/多発性骨髄腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p170-171, MCメディカ出版, 2005.
20) Hogendoorn PCW, Unni KK : Malignant lymphoma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 306, IARC Press, Lyon, 2002.
21) 河本圭司, 中嶋安彬 : 悪性リンパ腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p172-173, MCメディカ出版, 2005.
22) Sciot R, et al : Giant cell tumour. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 310, IARC Press, Lyon, 2002.
23) 河本圭司, 中嶋安彬 : 骨巨細胞腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p 175, MCメディカ出版, 2005.
24) Nelson SD, Mirra JM : Chordoma. In : Pathology and Genetics of Tumours of Soft Tissue and Bone (ed by Fletcher CDM, et al), p 316, IARC Press, Lyon, 2002.
25) 河本圭司, 中嶋安彬 : 転移性骨腫瘍. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p184-188, MCメディカ出版, 2005.
26) 河本圭司, 中嶋安彬 : 好酸球肉芽腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p198-199, MCメディカ出版, 2005.
27) 河本圭司, 中嶋安彬 : 線維性異形成. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p195-196, MCメディカ出版, 2005.
28) 河本圭司, 中嶋安彬 : 類表皮嚢胞/類皮嚢胞. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p201-202, MCメディカ出版, 2005.
29) 河本圭司, 中嶋安彬 : 頭蓋骨内髄膜腫. アトラス頭蓋骨学-基礎と臨床 (河本圭司編), p189-190, MCメディカ出版, 2005.
P.450 掲載の参考文献
3) Thurnher MM, Salzman KL : Ependymal tumor. In : Diagnostic lmaging : Brain, 2nd ed (ed by Osborn AG), pI-6-60-71, Amirsys, Manitoba, 2010.
7) 佐藤一史 : 粘液乳頭状上衣腫. 脳腫瘍の病理と臨床 (第2版) (久保田紀彦編), p112-115, 診断と治療社, 2008.
8) 柳下章 : 上衣腫. エキスパートのための脊椎脊髄疾患のMRI (第3版) (柳下章編), p 184-195, 三輪書店, 2015.
10) Pajtler KW, et al : Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27 : 728-743, 2015.
P.454 掲載の参考文献
P.458 掲載の参考文献
P.463 掲載の参考文献
13) Shih DJ, et al : Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 32 : 886-896, 2014.
P.468 掲載の参考文献
3) Hsu E, et al : Bone marrow metastasis in astrocytic gliomata. J Neurooncol 37 : 285-293, 1998.
P.472 掲載の参考文献
9) 柴崎尚ほか : 脳室腹腔吻合管を経由した悪性脳腫瘍の神経管外転移. 脳神経外科 5 : 71-79, 1977.
P.475 掲載の参考文献
3) 全国脳腫瘍統計 2001-2004 (the Brain Tumor Registry of Japan, 2001-2004).
8) Lynch TJ, et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to ge丘tinib. N Engl J Med 350 (21) : 2129-2139, 2004.
P.484 掲載の参考文献
1) Bailey P, Cushing H : A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlative Study of Prognosis, JB Lippincot, Philadelphia, London&Montreal, 1926.
P.490 掲載の参考文献
1) Brainard JA, et al : Frozen section evaluation of stereotactic brain biopsies : diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol Lab Med 121 : 481-484, 1997.
3) 横尾英明, 伊古田勇人 : 術中生検診断のポイント. 癌診療指針のための病理診断プラクティス-脳腫瘍 (青笹克之, 中里洋一編), p23-26, 中山書店, 2012.
P.494 掲載の参考文献
1) 平野朝雄, 冨安斉 : 染色. 神経病理を学ぶ人のために (第4版), p53-63, 医学書院, 2003.
2) 斎藤誠 : ヘマトキシリン・エオジン染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1011-1014, 1977.
3) 鬼頭つや子ほか : ニッスル染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1089-1091, 1977.
4) 鬼頭つや子ほか : ボディアン染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1091-1093, 1977.
5) 及川清, 石川喜美男 : ホルツァー染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1093-1094, 1977.
6) 高田多津男 : リンタングステン酸ヘマトキシリン染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1031-1032, 1977.
7) 鬼頭つや子, 松下正明 : ルクソールファスト青染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1094-1096, 1977.
8) 渡辺恒彦 : 鍍銀染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1034-1036, 1977.
9) 朝隈蓉子 : マッソントリクローム染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1029-1031, 1977.
10) 高田多津男 : ワンギーソン染色. Medical Technology-染色法のすべて- (只野寿太郎, 清水一男編) 5 (13) : 1033-1034, 1977.
P.499 掲載の参考文献
7) 南條博ほか : 迅速免疫染色. 病理と臨床 (臨時増刊号 ; 免疫組織化学診断と治療選択の指針) 32 : 52-58, 2014.
9) 赤上陽一 : 粒子分散型誘導流体を用いた加工法. 特許第359521号.
10) 特開2010-119388非接触撹拌方法, 非接触撹拌装置それを用いた核酸ハイブリダイゼーション反応方法反応装置, 試料中の核酸を検出する方法, 試料中の抗体を検出する方法, 及び検出装置.
11) 中村竜太ほか : 電界砥粒制御技術を応用した電界非接触微粒子撹拌技術の開発. 精密工学会誌 80 (9) : 862-866, 2014.
14) Hiroshima Y, et al : Rapid immunohistochemistry of IDH-1 for the intraoperative diagnosis of gliomas. Akita J Med 42 : 147-156, 2015.
P.508 掲載の参考文献
P.512 掲載の参考文献
2) 佐藤能啓 : 髄液細胞アトラス, 朝倉書店, 1987.
3) 山下純宏ほか : Cytospinを用いた脳腫瘍の髄液細胞診. 脳神経外科 7 : 751-758, 1979.
6) 藤本孟男 : 中枢神経白血病. メディチーナ 18 : 1882-1884, 1977.
P.517 掲載の参考文献

IX 脳腫瘍の治療

P.524 掲載の参考文献
P.527 掲載の参考文献
P.535 掲載の参考文献
P.539 掲載の参考文献
P.544 掲載の参考文献
1) 覚醒下手術ガイドライン (日本Awake Surgery学会編), 医学書院, 2013.
3) 村垣善浩ほか : 覚醒下マッピングとモニタリングを用いた手術. 脳神経外科ジャーナル 17 : 38-47, 2008.
7) 丸山隆志ほか : 覚醒下手術の現状と課題. 脳神経外科ジャーナル 22 : 597-604, 2013.
P.551 掲載の参考文献
2) 渋井壮一郎 (監修) : 光線力学診断用剤アラベル内用剤1.5g適正使用ガイド, 2013. [http://nobelpark.jp/product/alabel/alabel_gm.pdf]
11) Valdes PA, et al : δ-aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas : the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol 13 : 846-856, 2011.
18) 金子貞男 : AIA光線力学診断 (ALA-PDD) ガイドによる腫瘍摘出術. NS NOW 4 脳・脊髄腫瘍摘出のための引き出し 腫瘍摘出のコツとピットフォール, p84-95, メジカルビュー社, 2015.
20) Stummer W, et al ; European ALA Pediatric Brain Tumor Study Group : Predicting the "usefulness" of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors : a European survey. Acta Neurochir (Wien) 156 : 2315-2324, 2014.
P.557 掲載の参考文献
1) 天野耕作ほか : 経鼻前頭蓋底手術-ハイビジョン内視鏡による可視化-. Jpn J Neurosurg (Tokyo) 24 : 99-107, 2015.
4) Strychowsky J, et al : Purely endoscopic transsphenoidal surgery versus traditional microsurgery for resection of pituitary adenomas : systematic review. J Otolaryngol Head Neck Surg 40 : 175-185, 2011.
6) 川俣貴一 : 内視鏡下経蝶形骨手術の術中モニタリング. NS NOW No. 19 下垂体外科 Update 大きく変わった経蝶形骨手術 (寺本明編), p 13-22, メジカルビュー社, 2012.
11) 小野成紀ほか : 顕微鏡手術における神経内視鏡の役割 : 神経内視鏡と顕微鏡の使い分けの現状分析を中心に. Jpn J Neurosurg (Tokyo) 20 : 716-724, 2011.
12) 萩原雅和ほか : 後頭蓋窩における内視鏡手術の基本的知識. Jpn J Neurosurg (Tokyo) 22 : 379-387, 2013.
P.561 掲載の参考文献
P.569 掲載の参考文献
1) 非接触撹拌方法, 非接触撹拌装置, それを用いた核酸ハイブリダイゼーション反応方法反応装置試料中の核酸を検出する方法, 試料中の抗体を検出する方法, 及び検出装置. 特開2010-119388.
3) Minamiya Y, et al : Immunohistochemical staining method and immunohistochemical staining apparatus 13/151730 (米国特許).
4) 赤上陽一 : 粒子分散型誘導流体を用いた加工法. 特許第359521号.
6) 南條博, ほか : 迅速免疫染色. 免疫組織化学. 診断と治療選択の指針. 病理と臨床 32 (臨時増刊号) : 54-58, 2014.
11) Hiroshima Y, et al : Rapid immunohistochemistry of IDH-1 for the intraoperative diagnosis of gliomas. Akita J Med 42 : 147-156, 2015.
P.575 掲載の参考文献
2) 井内俊彦, 幡野和男 : 悪性グリオーマに対する高精度放射線治療. Jpn J Neurosurg 21 : 207-215, 2012.
4) 石内勝吾 : 粒子線治療の脳腫瘍への臨床応用と将来展望. Jpn J Neurosurg 22 : 117-124, 2013.
12) Dinh JQ, et al : Particle therapy for central nervous system tumors in pediatric and adult patients. Transl Cancer Res 1 : 137-149, 2012.
13) Greene-Schloesser D, et al : Radiation-induced brain injury : a review. Front Oncol 2 : 1-14, 2012.
14) Gondi V, et al : Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Inst Radiat Oncol Biol Phys 83 : 487-493, 2012.
P.582 掲載の参考文献
4) Reddy K et al : Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 58 : 714-721, 2014.
7) Gondi V, et al : Preservation of memory with conformal avoidance of the hippocampal neural stemcell compartment during whole-brain radiotherapy for brain metastases (RTOG O933) : a phase II multi-institutional trial. J Clin Oncol 32 : 3810-3816, 2014.
P.588 掲載の参考文献
P.597 掲載の参考文献
P.603 掲載の参考文献
1) Yamamoto M, et al : Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901) : a multi-institutional prospective observational study. Lancet Oncol 15 : 387-395, 2014.
15) Levin VA, et al : Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Biol Phys 79 : 1487-1495, 2011.
P.608 掲載の参考文献
10) Shibamoto Y, et al : The role of cerebrospinal fluid cytology in radiotherapy planning for intracranial germinoma. Int J Radiat Oncol Biol Phys 29 : 1089-1094, 1994.
P.614 掲載の参考文献
15) Mitteer RA, et al : Proton beam radiation induces DNA damage and cell apoptosis in glioma stem cells through reactive oxygen species. Sci Rep 5 : 13961, 2015.
P.621 掲載の参考文献
P.627 掲載の参考文献
4) Stupp R, et al : NovoTTF-100A versus physician's choice chemotherapy in recurrent gHoblastoma : a randomised phase III trial of a novel treatment modality. Eur J Cancer 48 (14) : 2192-2202, 2012.
P.634 掲載の参考文献
P.639 掲載の参考文献
1) Solero CL, et al : Controlled study with BCNU vs. CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme. Cancer Clin Trials 2143-48, 1979.
3) Levin VA, et al : Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64 : 237-244, 1980.
6) Kumabe T, et al : [Recurrence of intracranial germinoma initially treated with chemotherapy only]. No Shinkei Geka 30 : 935-942, 2002.
11) Wen PY, et al : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010.
P.644 掲載の参考文献
4) 西川亮ほか : 初回再発の退形成性星細胞腫患者に対するTemozolomide単剤投与の有効性および安全性の検討 多施設共同第II相試験. 癌と化学療法 33 (9) : 1279-1285, 2006.
P.648 掲載の参考文献
2) Gilbert MR, et al : A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Eng J Med 370 (8) : 699-708, 2014.
4) Presta LG, et al : Humanization of anti-vascular endotherial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57 : 4593-4599, 1997.
5) 小野哲, 山本信之 : 分子標的治療薬 抗体 ベバシズマブ 日本臨牀 67 (増刊号 1) : 263-268, 2009.
6) 青柳慶史朗ほか : Avastin. 日本臨牀 66 (増刊号 5) : 485-488, 2008.
9) Chinot OL, et al : Ethcacy and safety of bevacizumab plus standard combination temozolomide and radiotherapy in newly diagnosed glioblastoma : final results from AVAglio. ECC2013, Abstract No. 3301.
11) Herrlinger U, et al : Bevacizumab, irinotecan and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients : Updated results from the randomized multicenter GIARIUS trial. Program and abstracts of the European Cancer Congress 2013 ; Abstract 3300.
14) 宮武伸一 : 症候性放射線壊死の診断と治療. 脳神経外科 41 : 197-208, 2013.
15) 大江直行 : ベバシズマブ治療の実際と最新情報. 脳神経外科速報 25 : 74-80, 2015.
P.653 掲載の参考文献
7) Pallud J, et al ; Club de Neuro-Oncologie of the Societe Frangaise de Neurochirurgie : Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas : acontrolled propensity-matched analysis of a French multicenter cohort. Neuro Oncol 17 (12) : 1609-1619, 2015.
10) エーザイ株式会社 : ギリアデル脳内留置用剤7.7mg使用成績調査 (全国調査) 結果報告書.
P.660 掲載の参考文献
6) 原田薫雄ほか : 悪性グリオーマに対する放射線・MCNU・interferon-βを用いた放射線化学併用療法の治療成績. Jpn J Neurosurg 51 : 351-356, 1996.
8) Fukushima T, et al : Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas. Anticancer Res 23 : 4473-4481, 2003.
P.664 掲載の参考文献
3) Medical Research Council Brain Tumor Working Party : Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma : aMedical Research Council trial. J Clin Oncol 19 (2) : 509-518, 2001.
P.671 掲載の参考文献
6) 黒住和彦, 伊達勲 : グリオーマ血管新生, 浸潤に対する分子標的薬. 脳神経外科 43 : 691-701, 2015.
9) 黒住和彦, 伊達勲 : 臨床医のための最新脳神経外科, Vol. 45, 先端医療技術研究所, 2014.
14) http://www.clinicaltrials.gov
P.675 掲載の参考文献
11) Mas-Moruno C, et al : Cilengitide : the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10 : 753-768, 2010.
14) 黒住和彦, 伊達勲 : グリオーマ血管新生, 浸潤に対する分子標的薬. 脳神経外科 43 : 691-701, 2015.
P.686 掲載の参考文献
6) Shinojima N, et al : Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 : 6962-6970, 2003.
8) Batra SK et al : Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6 : 1251-1259, 1995.
10) Goldstein N, et al : Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 : 1311-1318, 1995.
23) Desjardins A, et al : Phase II Study of Panitumumab in Combination with Irinotecan for Malignant Glioma Patients. Neuro Oncol 13 (Suppl 3) : iii90, 2011.
24) Wersall P, et al : Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol Immunother 44 : 157-164, 1997.
27) A phase II study of surgical excision, temozolomide, radiotherapy, and anti-EGFR radioimmunotherapy (EXTRA) as adjuvant therapy in high-grade gliomas. J Radiat Oncol 3 : 347-353, 2014.
29) Ramos TC, et al : Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3 : report from a phase I/II trial. Cancer Biol Ther 5 : 375-379, 2006.
37) Mishima K, et al : Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res 61 : 5349-5354, 2001.
38) Luwor RB, et al : Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR Cancer Res 61 : 5355-5361, 2001.
46) Gan HK, et al : A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J Clin Oncol 31 (suppl ; abstr 2520) : 2013.
49) Gan HK et al : Phase I study of ABT-414 mono-or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). J Clin Oncol 33 (Suppl ; abstr 2016) : 2015.
51) Takasu S, et al : Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J Neurooncol 63 : 247-256, 2003.
P.693 掲載の参考文献
1) Ishida Y et al : Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J 11 : 3887-3895, 1992.
2) Parsa Ar, et al : Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat Med 13 : 84-88, 2007.
11) Wintterle S, et al : Expression of the B7-related molecule B7-H1 by glioma cells : a potential mechanism of immune paralysis. Cancer Res 63 : 7462-7467, 2003.
P.697 掲載の参考文献
4) Ikic D, et al : Application of human leucocyte interferon in patients with tumours of the head and neck. Lancet 1 : 1025-1027, 1981.
6) Nakamura O, et al : Effect of human fibroblast interferon on malignant brain tumors. No To Shinkei 35 : 905-911, 1983.
7) Yoshida J, et al : Combination therapy with IFN-beta, ACNU and radiation (IAR) in malignant brain tumors. Gan To Kagaku Ryoho 13 : 520-524, 1986.
9) Imanishi J : Interferon-alpha, beta, gamma. Gan To Kagaku Ryoho 21 : 2853-2858, 1994.
18) Nagai M : Clinical trials of human fibroblast interferon (Hu IFN-beta) on malignant brain tumors. Nihon Gan Chiryo Gakkai Shi 18 : 60-68, 1983.
19) Shitara N, et al : Efficacy of interferon-beta and interleukin-2 as cytokines for malignant brain tumor treatment. Gan To Kagaku Ryoho 14 : 3235-3244, 1987.
21) Yoshida J, et al : Combination therapy with HU IFN-beta and ACNU against malignant brain tumors, Part 1. Experimental study in vitro. Gan To Kagaku Ryoho 12 : 99-104, 1985.
27) Wakabayashi T, et al : A multicenter phase I trial of combination therapy with interferon-beta and temozolomide for high-grade gliomas (INTEGRA study) : the final report. J Neurooncol 104 : 573-577, 2011.
28) Wakabayashi T, et al : JCOG0911 : phase II trial of interferon and temozolomide versus temozolomide alone followed by radiotherapy for newly-diagnosed glioblastoma (Japan Clinical Oncology Group : INTEGRA study). In : 19th Annual Scientific Meeting of Society of Neuro-Oncology. 2014 ; Meeting abstract.

X 小児脳腫瘍

P.705 掲載の参考文献
1) 小児がん診療ガイドライン 2011年版 (日本小児がん学会編), 全原出版, 2011.
3) Mack SC, et al : Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506 : 445-450, 2014.
14) 石田也寸志 : 小児脳腫瘍の晩期合併症-長期フォローアップの重要性. 小児がん 47 : 396-403, 2010.
15) 石田也寸志 : 小児脳腫瘍の晩期障害. 日本小児学会会誌 108 : 368-379, 2004.
P.712 掲載の参考文献
6) Ashley DM, et al : Induction chemotherapy and conformal radiation therapy for very young children with nonmetastatic medulloblastoma : Children's Oncology Group study P9934. J Clin Oncol 30 : 3181-3186, 2012.
8) Tarbell NJ, et al : High-risk medulloblastoma : a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol 31 : 2936-2941, 2013.
P.717 掲載の参考文献
2) 宇津木聡ほか : Atypical teratoid/rhabdoid tumor (AT/RT) -広範なependymal differentiationを伴った症例. 脳外誌 7 : 507-512, 1998.
4) Judkins AR, et al : Atypical teratoid/rhabdoid tumor. In : WHO Classification of Tumours of the Central Nervous System (ed by Louis DN, et al), p 147-149, IARC Press, Lyon, 2007.
9) Tanizaki Y, et al : Atypical teratoid/rhabdoid tumor arising from the spinal cord : case report and review of the literature. Clin Neuropathol 25 : 81-85, 2006.
10) Meyers SP, et al : Primaly intracranial atypical teratoid/rhabdoid tumors of infancy and childhood : MRI features and patient outcomes. AJNR 27 : 962-971, 2006.
P.726 掲載の参考文献
1) Massimino M, et al : Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro Oncol, 2016. [Epub ahead of print]
6) Pajtler KW, et al : Molecular Classhication of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell 27 : 728-743, 2015.
18) Timmermann B, et al : Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood : Results of the Geman prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol 46 : 287-295, 2000.
19) Parker M, et al : C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature 506 : 451-455, 2104.
P.732 掲載の参考文献
1) The Committee of Brain Tumor Registry of Japan. Report of Brain Tumor Registry of Japan (1984-2000), 12th ed. Neurol Med Chir (Tokyo) 49 (Suppl) : 1-96, 2009.
4) 篠田淳, 坂井昇 : 脳幹グリオーマ. 脳神経外科学大系 第13巻 小児脳神経外科 (山浦晶ほか編), p357-359, 中山書店, 2004.
5) Choux M, et al : Brainstem tumors. In : Pediatric Neurosurgery (ed by Choux M, et al), p 471-492, Churchill Livingstone, London, 1999.
6) Blum KS, Goodrichi JT : Brain stem tumors. In : Tumors of the Pediatric Central Nervous System (ed by Keating RF, et al), p 206-220, Thieme, New York, 2001.
14) Morales LMS, et al : Future clinical trials in DIPG : bringing epigenetics to the clinic. Front Oncol 5, Article 148 : 1-5, 2015.
P.736 掲載の参考文献
5) Kornreich L, et al : Optic pathway glioma : correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol 22 (10) : 1963-1969, 2001.
8) Hartel PH, et al : Malignant optic nerve glioma (glioblastoma multiforme) : A case report and literature review. W V Med J 102 (4) : 29-31, 2006.
P.739 掲載の参考文献
P.743 掲載の参考文献
3) Rosenblum MK, et al : CNS germ cell tumours. In : WHO Classification of Tumours of the Nervous System, 3rd ed (ed by Louis DN, et al), p 197-204, IARC, Lyon, 2007.
7) Hedlund GL : Germinoma In Diagnostic Imaging : Brain (ed by Osborn AG), p I-6-132-135, Amirsys Inc, Salt Lake City, 2004.
18) 西川亮 : 6. 胚細胞腫瘍 (1) ジャーミノーマ. 別冊日本臨牀 神経症候群 (第2版), p347-351, 日本臨牀社, 2014.

XI 転移性脳腫瘍

P.751 掲載の参考文献
1) Tabouret E, et al : Recent trends in epidemiology of brain metastases : an overview. Anticancer Res 32 : 4655-4662, 2012.
12) Jeong HJ, et al : Usefulness of whole-body 18F-FDG PET in patients with suspected metastatic brain tumors. J Nucl Med 43 : 1432-1437, 2002.
P.755 掲載の参考文献
5) Kocher M, et al : Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases : results of the EORTC 22952-26001 study. J Clin Oncol 29 (2) : 134-141, 2011.

XII 特論

P.762 掲載の参考文献
P.768 掲載の参考文献
P.774 掲載の参考文献
P.778 掲載の参考文献
P.784 掲載の参考文献
14) Ribas A, et al : Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 31 : 616-622, 2013.

最近チェックした商品履歴

Loading...